Anti-CD40 Ab- or 8-oxo-dG-enhanced Treg cells reduce development of experimental autoimmune encephalomyelitis via down-regulating migration and activation of mast cells

Journal of Neuroimmunology

Volumn 260, Issue 1-2, 2013, Pages 60-73

  Hong, Gwan Ui ^a   Kim, Nam Goo ^a   Jeoung, Dooil ^b   Ro, Jai Youl ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Kangwon National University   (South Korea)

Author keywords

8 oxo dG; Anti CD40 Ab; EAE; Inflammatory cytokines; Mast cells; Treg cells

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ANTIBODY; CALCIUM ION; CD134 ANTIGEN; CD31 ANTIGEN; CD4 ANTIGEN; CD40 ANTIBODY; CHEMOKINE RECEPTOR CCR2; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 35; LEUKOTRIENE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; OX40 LIGAND; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CELL ACTIVATION; CELL MIGRATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; FEMALE; GENE EXPRESSION; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD40; AUTOANTIBODIES; CALCIUM; CELL COMMUNICATION; CELL MOVEMENT; DEOXYGUANOSINE; DOWN-REGULATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; INTERLEUKIN-17; LEUKOTRIENES; LYMPHOCYTE ACTIVATION; MAST CELLS; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878646429     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.04.002     Document Type: Article

References (59)

1. Abonia J.P., Hallgren J., Jones T., Shi T., Xu Y., Koni P., Flavell R.A., Boyce J.A., Austen K.F., Gurish M.F. Alpha-4 integrins and VCAM-1, but not MAdCAM-1, are essential for recruitment of mast cell progenitors to the inflamed lung. Blood 2006, 108:1588-1594.
2. Arinobu Y.H., Iwasaki M.F., Grish S., Mizuso H., Shigematsu H., Ozawa D.G. Developmental checkpoint of the basophil/mast cell lineages in adult murine hematopoiesis. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18105-18110.
3. Banchereau J., Pascual V., O'Garra, A. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat. Immunol. 2012, 13:925-931.
4. Bennett J.L., Blanchet M.R., Zhao L., Zbytnuik L., Antignano F., Gold M., Kubes P., McNagny K.M. Bone marrow-derived mast cells accumulate in the central nervous system during inflammation but are dispensable for experimental autoimmune encephalomyelitis pathogenesis. J. Immunol. 2009, 182:5507-5514.
5. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., Weiner H.L., Kuchroo V.K. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 2006, 441:235-238.
6. Boon L., Brok H.P., Bauer J., Ortiz-Buijsse A., Schellekens M.M., Ramdien-Murli S., Blezer E., van Meurs M., Ceuppens J., de Boer M., 't Hart, B.A., Laman J.D. Prevention of experimental autoimmune encephalomyelitis in the common marmoset (Callithrix jacchus) using a chimeric antagonist monoclonal Ab against human CD40 is associated with altered B cell responses. J. Immunol. 2001, 167:2942-2949.
7. + regulatory T cells. Eur. J. Immunol. 2008, 38:1643-1653.
8. Burchill M.A., Yang J., Vang K.B., Farrar M.A. Interleukin-2 receptor signaling in regulatory T cells development and homeostasis. Immunol. Lett. 2007, 114:1-8.
9. Chaturvedi V., Collison L.W., Guy C.S., Workman C.J., Vignali V.V. Cutting edge: human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J. Immunol. 2012, 186:6661-6666.
10. Collington S.J., Hallgren J., Pease J.E., Jones T.G., Rollins B.J., Westwick J., Austen K.F., Williams T.J., Gurish M.F., Weller C.L. The role of the CCL2/CCR2 axis in mouse mast cell migration in vitro and in vivo. J. Immunol. 2010, 184:6114-6123.
11. Collison L.W., Workman C.J., Kuo T.T., Boyd K., Wang Y., Vignali K.M., Cross R., Sehy D., Blumberg R.S., Vignali D.A. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450(7169):566-569.
12. Couturier N., Zappulla J.P., Lauwers-Cances V., Uro-Coste E., Delisle M.B., Clanet M., Montagne L., Van der Valk P., Bö L., Liblau R.S. Mast cell transcripts are increased within and outside multiple sclerosis lesions. J. Neuroimmunol. 2008, 195:176-185.
13. del Rio R., Noubade R., Saligrama N., Wall E.H., Krementsov D.N., Poynter M.E., Zachary J.F., Thurmond R.L., Teuscher C. Histamine H4 receptor optimizes T regulatory cell frequency and facilitates anti-inflammatory responses within the central nervous system. J. Immunol. 2012, 188:541-547.
14. Dudeck A., Leist M., Rubant S., Zimmermann A., Dudeck J., Boehncke W.H., Maurer M. Immature mast cells exhibit rolling and adhesion to endothelial cells and subsequent diapedesis triggered by E- and P-selectin, VCAM-1 and PECAM-1. Exp. Dermatol. 2010, 19:424-434.
15. Fransson M., Piras E., Burman J., Nilsson B., Essand M., Lu B., Harri R.A., Magnusson P.U., Brittebo E., Loskog A.S. CAR/Foxp3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery. J. Neuroinflammation 2012, 9(1):112.
16. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 2006, 354:942-955.
17. + regulatory T cell interactions. Eur. J. Immunol. 2011, 41:1872-1882.
18. Gandhi R., Laroni A., Weiner H.L. Role of the innate immune system in the pathogenesis of multiple sclerosis. J. Neuroimmunol. 2010, 221:7-14.
19. Ganeshan K., Bryce P.J. Regulatory T cells enhance mast cell production of IL-6 via surface-bound TGF-β. J. Immunol. 2012, 188:594-603.
20. + regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity 2008, 29(5):771-781.
21. Haas J., Fritzsching B., Trübswetter P., Korporal M., Milkova L., Fritz B., Vobis D., Krammer P.H., Suri-Payer E., Wildemann B. Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. J. Immunol. 2007, 179:1322-1330.
22. Hadaschik B., Su Y., Huter E., Ge Y., Hohenfellner M., Beckhove P. Antigen specific T-cell responses against tumor antigens are controlled by regulatory T cells in patients with prostate cancer. J. Urol. 2012, 4:1458-1465.
23. Iyoda M., Shibata T., Kawaguchi M., Hizawa N., Yamaoka T., Kokuba F., Akizawa T. IL-17A and IL-17F stimulate chemokines via MAPK pathways (ERK1/2 and p38 but not JNK) in mouse cultured mesangial cells: synergy with TNF-alpha and IL-1beta. Am. J. Physiol. Renal Physiol. 2010, 298(3):F779-F787.
24. + regulatory T cells. Transpl. Immunol. 2011, 24:113-118.
25. Jin W., Qi S., Luo H. T cell-specific deletion of EFNB2 minimally affects T cell development and function. Mol. Immunol. 2012, 4:141-147.
26. Kang Z., Altuntas C.Z., Gulen M.F., Liu C., Giltiay N., Qin H., Liu L., Qian W., Ransohoff R.M., Bergmann C., Stohlman S., Tuohy V.K., Li X. Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. Immunity 2010, 32(3):414-425.
27. Kap Y.S., Laman J.D., 't Hart, B.A. Experimental autoimmune encephalomyelitis in the common marmoset, a bridge between rodent EAE and multiple sclerosis for immunotherapy development. J. Neuroimmune Pharmacol. 2010, 5:220-230.
28. Kashyap M., Thornton A.M., Norton S.K., Barnstein B., Macey M., Brenzovich J., Shevach E., Leonard W.J., Ryan J.J. Cutting edge: CD4 T cell-mast cell interaction alters IgE receptor expression and signaling. J. Immunol. 2008, 180:2039-2043.
29. Kim D.Y., Jeoung D., Ro J.Y. Signaling pathways in the activation of mast cells cocultured with astrocytes and colocalization of both cells in experimental allergic encephalomyelitis. J. Immunol. 2010, 185:273-283.
30. Kim D.Y., Hong G.U., Ro J.Y. Signal pathways in astrocytes activated by cross-talk between of astrocytes and mast cells through CD40-CD40L. J. Neuroinflammation 2011, 8:25.
31. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 cells. Annu. Rev. Immunol. 2009, 27:485-517.
32. Krüger P.G. Mast cells and multiple sclerosis: a quantitative analysis. Neuropathol. Appl. Neurobiol. 2001, 27:275-280.
33. Lee S.H., Han S.T., Choi S.W., Sung S.Y., You H.J., Ye S.K. Inhibition of Rac and Rac-linked function by 8-oxo-2'-deoxyguanosine in murine macrophages. Free Radic. Res. 2009, 43:78-84.
34. -sh) mice develop earlier and more severe experimental autoimmune encephalomyelitis due to absence of immune suppression. J. Immunol. 2011, 187:274-282.
35. Li X., Mai J., Virtue A., Yin Y., Gong R., Sha X., Gutchigian S., Frisch A., Hodge I., Jiang X., Wang H., Yang X.-F. IL-35 is a novel responsive anti-inflammatory cytokine-a new system of categorizing anti-inflammatory cytokines. PLoS One 2012, 7(3):e33628.
36. Liu J.Q., Liu Z., Zhang X., Shi Y., Talebian F., Carl J.W., Yu C., Shi F.D., Whitacre C.C., Trgovcich J., Bai X.F. Increased Th17 and regulatory T cell responses in EBV-induced gene 3-deficient mice lead to marginally enhanced development of autoimmune encephalomyelitis. J. Immunol. 2012, 188:3099-3106.
37. Lu L.F., Lind E.F., Gondek D.C., Bennett K.A., Gleeson M.W., Pino-Lagos K., Scott Z.A., Coyle A.J., Reed J.L., Van Snick J., Strom T.B., Zheng X.X., Noelle R.J. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 2006, 442(7106):997-1002.
38. Marson A., Kretschmer K., Frampton G.M., Jacobsen E.S., Polansky J.K., MacIsaac K.D., Levine S.S., Fraenkel E., von Boehmer H., Young R.A. Foxp3 occupancy and regulation of key target genes during T cell stimulation. Nature 2007, 445:931-935.
39. Ono M., Yaguchi H., Ohkura N., Kitabayashi I., Nagamura Y., Nomura T., Miyachi Y., Tsukada T., Sakaguchi S. Foxp3 controls regulatory T cell function by interacting with AML1/Runx1. Nature 2007, 446:685-689.
40. + T cell-mediated suppression by dendritic cells. Science 2003, 299(5609):1033-1036.
41. + effector T cells. Int. Immunol. 2008, 20:421-431.
42. Piconese S., Gri G., Tripodo C., Musio S., Gorzanelli A., Frossi B., Pedotti R., Pucillo C.E., Colombo M.P. Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation. Blood 2009, 114(13):2639-2648.
43. Ro J.Y., Kim D.Y., Lee S.H., Park J.W., Chung M.H. Effects of 7,8-dihydro-8-oxo-deoxyguanosine on antigen challenge in ovalbumin-sensitized mice may be mediated by suppression of Rac. Br. J. Pharmacol. 2009, 158:1743-1752.
44. Sayed B.A., Christy A.L., Walker M.E., Brown M.A. Meningeal mast cells affect early T cell central nervous system infiltration and blood-brain barrier integrity through TNF: a role for neutrophil recruitment?. J. Immunol. 2010, 184:6891-6900.
45. Sayed B.A., Walker M.E., Brown M.A. Cutting edge: mast cells regulate disease severity in a relapsing-remitting model of multiple sclerosis. J. Immunol. 2011, 186:3294-3298.
46. Setoguchi R., Hori S., Takahashi T., Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 2005, 201:723-735.
47. Shapira E., Brodsky B., Proscura E., Nyska A., Erlanger-Rosengarten A., Wormser U. Amelioration of experimental autoimmune encephalitis by novel peptides: involvement of T regulatory cells. J. Autoimmun. 2010, 35:98-106.
48. Sweeney C.M., Tubridy N., Mills K.H. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin. Exp. Immunol. 2010, 162:1-11.
49. Theoharides T.C., Kempuraj D., Kourelis T., Manola A. Human mast cells stimulate activated T cells: implications for multiple sclerosis. Ann. N. Y. Acad. Sci. 2008, 1144:74-82.
50. Tinkum K.L., Marpengan L., White L.S., Sun J., Herzog E.D., Piwnica-Worms D., Piwnica-Worms H. Bioluminescence imaging captures the expression and dynamics of endogenous p21 promoter activity in living mice and intact cells. Mol. Cell. Biol. 2011, 18:3759-3772.
51. Valzasina B., Guiducci C., Dislich H., Killeen N., Weinberg A.D., Colombo M.P. Triggering of OX40 (CD134) on CD4(+)CD25(+) T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 2005, 105:2845-2851.
52. + regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 2004, 199:971-979.
53. Von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat. Immunol. 2005, 6:338-344.
54. Weiner H.L. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?. Ann. Neurol. 2009, 65:239-248.
55. Zepp J., Wu L., Li X. IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. Cell 2011, 32(5):232-239.
56. Zhang L., Zhao Y. The regulation of Foxp3 expression in regulatory CD4(+)CD25(+)T cells: multiple pathways on the road. J. Cell. Physiol. 2007, 211(3):590-597.
57. Zhang J., Alcaide P., Liu L., Sun J., He A., Luscinskas F.W., Shi G.P. Regulation of endothelial cell adhesion molecule expression by mast cells, macrophages, and neutrophils. PLoS One 2011, 6(1):e14525-e14538.
58. Zheng Y., Josefowicz S.Z., Kas A., Chu T.T., Gavin M.A., Rudensky A.Y. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 2007, 445:936-940.
59. + regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006, 108:1571-1579.